Dr Lisa Holland
Lisa Holland completed an undergraduate degree in Biochemistry with Microbiology at Lancaster University and a PhD in Molecular Microbiology at the University of Nottingham. After spending time as a secondary school teacher Lisa joined CTSU in 2006 as a member of the Vascular Overviews Group.
Lisa has worked on the meta-analyses of clinical trials of statins (Cholesterol Treatment Trialists Collaboration), of non-steroidal anti-inflammatory drugs (Coxib and NSAID Trialists Collaboration), and of angiotension receptor blockers for the treatment of Marfan Syndrom. She is now Research Facilitator for the Mexico City Prospective Study – a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A. et al, (2022), Lancet
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
BAIGENT C. et al, (2022), The Lancet
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.
Marthi A. et al, (2018), J Am Soc Nephrol, 29, 2015 - 2027
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
Scally B. et al, (2018), Lancet Gastroenterol Hepatol, 3, 231 - 241